Clinical trialNCT02923778Active, not recruitingPhase 2Interventional

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

SponsorNational Cancer Institute (NCI)Enrollment40LeiomyosarcomaLiposarcomaSarcoma G2Sarcoma G3Soft Tissue SarcomaSoft Tissue Sarcoma of the Trunk and Extremities+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery (resectable). Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons. electrons, or protons to kill tumor cells and shrink tumors. Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Steven I Robinson
Mayo Clinic Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada

United States

Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
Siteman Cancer Center-South County
St Louis, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Dartmouth Hitchcock Medical Center/dartmouth Cancer Center
Lebanon, New Hampshire, United States
Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
Ut Md Anderson Cancer Center
Houston, Texas, United States
Vcu Massey Comprehensive Cancer Center
Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Herpesvirus 1, human →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2019
Primary completion: 29 Dec 2026
Completion: 29 Dec 2026
Last update posted: 20 Jul 2026
Registered enrollment: 40
Registry id: NCT02923778

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.